The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase ...

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...

European Commission approves Sanofi & Regeneron’s Dupixent to treat young children with chronic spontaneous urticaria: Paris Wednesday, April 15, 2026, 09:00 Hrs [IST] The Europ ...

Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...

Replimune received a second FDA complete response letter for RP1 in advanced melanoma, raising questions about the viability of its oncolytic immunotherapy program. Replimune Group received a complete ...

A video showing policemen beating young women is going viral on social media. Gautam Buddh Nagar Police claim it is ...

Last year, tungsten diselenide (WSe2) had its magic moment. Two independent research groups discovered "magic angles" at ...

ALBANY, N.Y. — New York Governor Kathy Hochul is announcing the start of phase two of the School Tax Relief (STAR) program benefit season. For phase two, eligible homeowners that live in communities ...

Despite the initiation of a phase 3 confirmatory trial, the FDA remains unsatisfied with the interpretability of phase 2 data for Replimune’s oncolytic immunotherapy.

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.